Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Change in Account Payables (2020 - 2025)

Historic Change in Account Payables for Ovid Therapeutics (OVID) over the last 6 years, with Q3 2025 value amounting to -$2.2 million.

  • Ovid Therapeutics' Change in Account Payables fell 1144.28% to -$2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$999000.0, marking a year-over-year decrease of 16691.23%. This contributed to the annual value of -$512000.0 for FY2024, which is 12925.71% down from last year.
  • As of Q3 2025, Ovid Therapeutics' Change in Account Payables stood at -$2.2 million, which was down 1144.28% from $2.0 million recorded in Q2 2025.
  • Over the past 5 years, Ovid Therapeutics' Change in Account Payables peaked at $2.5 million during Q4 2023, and registered a low of -$4.9 million during Q1 2022.
  • Its 5-year average for Change in Account Payables is -$436018.2, with a median of -$114000.0 in 2023.
  • Its Change in Account Payables has fluctuated over the past 5 years, first surged by 22005.88% in 2021, then crashed by 106074.77% in 2025.
  • Over the past 5 years, Ovid Therapeutics' Change in Account Payables (Quarter) stood at $2.1 million in 2021, then plummeted by 55.91% to $919844.0 in 2022, then surged by 170.26% to $2.5 million in 2023, then crashed by 80.65% to $481000.0 in 2024, then plummeted by 565.7% to -$2.2 million in 2025.
  • Its Change in Account Payables was -$2.2 million in Q3 2025, compared to $2.0 million in Q2 2025 and -$1.2 million in Q1 2025.